Erythropoietin enhances immunostimulatory properties of immature dendritic cells.

Authors: Rocchetta, F  Solini, S  Mister, M  Mele, C  Cassis, P  Noris, M  Remuzzi, G  Aiello, S 
Citation: Rocchetta F, etal., Clin Exp Immunol. 2011 Aug;165(2):202-10. doi: 10.1111/j.1365-2249.2011.04417.x. Epub 2011 Jun 7.
Pubmed: (View Article at PubMed) PMID:21649646
DOI: Full-text: DOI:10.1111/j.1365-2249.2011.04417.x

Dendritic cells (DCs) are the most potent antigen-presenting cells and play a crucial role by modulating the T cell immune response against infective agents, tumour antigens and alloantigens. The current study shows that differentiating bone marrow (BM)-derived DCs but not fully differentiated DCs are targets of erythropoietin (EPO). Indeed, DCs emerging from rat bone marrow, but not splenic DCs, express the EPO receptor (Epo-R) and respond to EPO stimulation displaying a more activated phenotype with increased CD86, CD40 and interleukin (IL)-12 expression levels and a higher allostimulatory capacity on T cells than untreated DCs. Moreover, results here presented show that EPO up-regulates Toll-like receptor (TLR)-4 in differentiating DCs rendering these cells more sensitive to stimulation by the TLR-4 ligand lipopolysaccharide (LPS). Indeed, DCs treated with EPO and then stimulated by LPS were strongly allostimulatory and expressed CCR7, CD86, CD40, IL-12 and IL-23 at higher levels than those observed in DCs stimulated with LPS alone. It is tempting to speculate that EPO could act as an additional danger signal in concert with TLR-4 engagement. Thus, EPO, beyond its erythropoietic and cytoprotective effects, turns out to be an immune modulator.


Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10401062
Created: 2015-09-23
Species: All species
Last Modified: 2015-09-23
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.